Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3792 in advanced solid tumors
NCT06907628Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Biologic, Antineoplastics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-3792 in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 21 days, Recommended Phase 2 Dose up to 21 days and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
SHR-3792
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06907628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907628.